Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18861544 | 0.96 | GLS (0.47) | GLSSMN1; SMN2 | |
| SCHEMBL18861483 | 0.96 | GLS (0.47) | GLSSMN1; SMN2 | |
| SCHEMBL18861608 | 0.93 | GLS (0.46) | GLSSMN1; SMN2 | |
| SCHEMBL18861600 | 0.92 | GLS (0.42) | GLS | |
| SCHEMBL18860893 | 0.92 | GLS (0.56) | GLS | |
| SCHEMBL17115623 | 0.86 | GLS (0.39) | GLS | |
| SCHEMBL17115625 | 0.86 | GLS (0.39) | GLS | |
| SCHEMBL18861596 | 0.85 | GLS (0.51) | GLSSMN1; SMN2 | |
| SCHEMBL18861467 | 0.84 | GLS (0.48) | GLSSMN1; SMN2 | |
| SCHEMBL18861607 | 0.84 | GLS (0.39) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000479-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | GLS 1/4885SMN1; SMN2 3566/4885TYK2 3474/4885 |
| US-10000479-B2 | Compounds and their methods of use | GLS, GLS2, GLUL | GLS 1/4885SMN1; SMN2 3566/4885TYK2 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.